Symphogen A/S

Symphogen (Lyngby, Denmark) is a clinical-stage biopharmaceutical company developing recombinant antibody mixtures: a new class of antibody therapeutics for the treatment of oncology, hematology, and infectious diseases. The development of antibody mixtures represents a significant opportunity for selection based on both diversity and specificity, thereby capturing the optimal characteristics of the natural human immune response. Symphogen has entered into several partnerships with pharmaceutical companies in the US, Europe, and Japan.
Søren Lemonius

Managing Partner

Mobile: +45 40 81 48 89
Email Click here to contact